Proposal to reduce GMP requirement for P1 trials drugs

This rule change would reduce by a few million dollars the cost of producing a drug for initial safety trials. This would, however, INCREASE the safety risk (slightly). I guess the clinical folks feel good about non-GMP manufacturing processes.